Recent developments on DHEA supplementation in the substitutive therapy of primary adrenal insufficiency

Bibliography

• ADDISON T: The constitutional and local effects of diseases of the suprarenal capsules. In a collection of the published writing of the late Thomas Addison, MD, physician to: Guy's Hospital. London: New Sydenham Society 1868. Reprinted in Medical Classics (1937) 2:244–293.
   Google Scholar
• LAURETI S, VECCHI L, SANTEUSANIO F, FALORNI A: Is the prevalence of Addison's disease underestimated? j Chit. Eridocnhol Metab. (1999) 84:1762.
   Google Scholar
• LAURETI S, ARVAT E, CANDELORO P et al: Low dose (11.4 ACTH test in the evaluation of adrenal dysfunction in pre-clinical Addison's disease. Clin. Eridocnhol (2000) 53:107–115
   Google Scholar
• •A study demonstrating that the ACTH low dose test has a high diagnostic sensitivity and specificity for mild forms of PAT.
   Google Scholar
• DICKSTEIN G: Hypothalamo-pituitary-adrenal axis testing: nothing is sacred and caution in interpretation is needed. CM]. Endocrine]. (2001) 54:15–16.
   PubMed Web of Science ®Google Scholar
• OELKERS W: Adrenal insufficiency. N Engl. J. Med. (1996) 335:1206–1212.
   PubMed Web of Science ®Google Scholar
• LAURETI S, AUBOURG E CALCINARO F et al.: Etiological diagnosis of primary adrenal insufficiency using an original flowchart of immune and biochemical markers. J CM]. Endocrine]. Metab. (1998) 83:3163–1368.
   Google Scholar
• WINQVIST 0, KARLSSON FA, KAMPE 0: 21-hydroxylase, a major autoantigen in idiopathic Addison's disease. Lancet (1992) 339:1559–1562.
   PubMed Web of Science ®Google Scholar
• BEDNAREK J, FURMANIAK J, WEDLOK N etal.: Steroid 21-hydroxylase is a major autoantigen involved in adult onset autoimmune Addison's disease. FEBS Lett. (1992) 309:51–55.
   Google Scholar
• FALORNI A, NIKOSHKOV A, LAURETI S et al.: High diagnostic accuracy for idiopathic Addison's disease with a sensitive radiobinding assay for autoantibodies against recombinant human 21-hydroxylase. I CM]. Endocrine]. Metab. (1995) 80:2752–2755.
   PubMed Web of Science ®Google Scholar
• COLLS J, BETTERLE C, VOLPATO M et al.: Immunoprecipitation assay for autoantibodies to steroid 21-hydroxylase in autoimmune adrenal diseases. CM]. Chem. (1995) 41:375–380.
   Google Scholar
• TANAKA H, PEREZ MS, POWELL Met al.: Steroid 21-hydroxylase autoantibodies: measurements with a new immunoprecipitation assay. I CM]. Endocrine]. Metab. (1997) 82:1440–1446.
   Google Scholar
• FALORNI A, LAURETI S, NIKOSHKOV A et al.: 21-hydroxylase autoantibodies in adult patients with endocrine autoimmune diseases are highly specific for Addison's disease. Clin. Exp. Immune] (1997) 107:341–346.
   PubMed Web of Science ®Google Scholar
• LAURETI S, FALORNI A, VOLPATO M et al.: Absence of circulating adrenal autoantibodies in adult-onset X-linked adrenoleukodystrophy. Herm. Metab. Res. (1996) 28:319–322.
   PubMed Web of Science ®Google Scholar
• LAURETI S, CASUCCI G, SANTEUSANIO F et al.: X-linked adrenoleukodystrophy is a frequent cause of 'idiopathic' Addison's disease in young-adult male patients. j Clin. Endocnno] Metab. (1996) 81:470–474.
   PubMed Web of Science ®Google Scholar
• ZANARIA E, MUSCATELLI F, BARDONI B et a]: An unusual member of the nuclear hormone receptor superfamily responsible for X-linked adrenal hypoplasia congenita. Nature (1994) 372(6507):635–641.
   PubMed Web of Science ®Google Scholar
• CLARK AJL, MC LOUGHLIN L, GROSSMAN A: Familial glucocorticoid deficiency associated with point mutation in the adrenocorticotropin receptor. Lancet (1993) 341:461.
   PubMed Web of Science ®Google Scholar
• MOSER HW: Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy. Brain (1997) 120:1485.
   PubMed Web of Science ®Google Scholar
• AUBOURG P. The expanding world of primary adrenal insufficiency. Eur. Endocrine]. (1997) 137:10.
   PubMed Web of Science ®Google Scholar
• MUSCATELLI E STROM TM, WALKER AP et al. Mutations in the DAX-1 gene rise to both X-linked adrenal hypoplasia congenita and hypogonadotropic hypogonadism. Nature (1994) 372(6507):672–676.
   PubMed Web of Science ®Google Scholar
• WEBER A, CLARK AJL: Mutations of the ACTH receptor gene are only one cause of familial glucocorticoid deficiency. Hum. Me] Gen. (1994) 3:585.
   Web of Science ®Google Scholar
• TSIGOS C, ARAI K, LATRONICO AC, DIGEORGE A, RAPAPORT R, CHROUSOS GP: A novel mutation of the adrenocorticotropin receptor (ACTH-R) gene in a family with syndrome of isolated glucocorticoid deficiency, but no ACTH-R abnormalities in two families with the triple A syndrome. j Clin. Endocnno] Metab. (1995) 80:2186.
   PubMed Web of Science ®Google Scholar
• ALLGROVE J, CLAYDEN GS, GRANT BD, MCCAULAY JC: Familial glucocorticoid deficiency with achalasia of the cardia and deficient tear production. Lancet (1978) I:1284.
   Google Scholar
• WEBER A, WIENKER TF, JUNG M et al.: Linkage of the gene for the triple A syndrome to chromosome 12q13 near the Type II keratin gene cluster. Hum. Me] Genet. (1996) 5:2061.
   PubMed Web of Science ®Google Scholar
• HANDSCHUG K, SPERLING S, KIM YOON SJ et al.: Triple A syndrome is caused by mutations in AAAS a new WD-repeat protein gene. Hum. Me] Gen. (2001) 10:283: 290.
   Google Scholar
• TULLIO-PETEL A, SALOMON R, HADJ-RABIA S et al.: Mutant WD-repeat protein in triple-A syndrome. Nat. Genet. (2000) 26:332–335.
   PubMed Web of Science ®Google Scholar
• ESTEBAN NV, LOUGHLIN T, YERGEY AL et al.: Daily cortisol production rate in man determined by stable isotope dilution/ mass spectrometry. I Clin. Endocrine] Metab. (1991) 72:39–45.
   PubMed Web of Science ®Google Scholar
• PEACEY SR, GUO CY, ROBINSON AM et al.: Glucocorticoid replacement therapy: are patients over treated and does it matter? Clin. Endocrine] (1997) 46:255–261.
   Google Scholar
• •A study suggesting that a high proportion of patients on conventional corticosteroid replacement therapy are overtreated or on inappropriate replacement regimen.
   Google Scholar
• BESSER JM, JEFFCOATE WJ: Adrenal disease. Br Med .j (1976) 1:448–451.
   PubMed Web of Science ®Google Scholar
• ZELISSEN PMJ, CROUGHS, VAN RIJK PP, RAYMAKERS JA: Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison's disease. Ann. Intern. Med. (1994) 120:207–210.
   PubMed Web of Science ®Google Scholar
• GROVES RV, TOMS GC, HOUGHTON BJ, MONSON JP: Corticosteroid replacement therapy: twice or thrice daily? J Royal Soc. Med. (1988) 81:514–516.
   Web of Science ®Google Scholar
• HOWLETT T: An assessment of optimal hydrocortisone replacement therapy. Clin. Endocnno] (1997) 46:263–268.
   PubMed Web of Science ®Google Scholar
• •The data obtained in this study indicate that an optimal replacement is achieved with a thrice daily hydrocortisone regimen.
   Google Scholar
• MONSON JP: The assessment of glucocorticoid replacement therapy. Clin Endocnno] (1997) 46:269–270.
   PubMed Web of Science ®Google Scholar
• SCOTT RS, DONALD RA, ESPINER EA: Plasma ACTH and cortisol profiles in Addisonian patients receiving conventional substitution therapy. Clin Endocnno] (Oxf) (1978) 9:571–576.
   PubMed Web of Science ®Google Scholar
• TRAINER PJ: Urinary free cortisol in the assessment of hydrocortisone replacement therapy. Herm. Metab. Res. (1993) 25:117–120.
   PubMed Web of Science ®Google Scholar
• OELKERS W, BUCHEN S, DIEDERICH S, KRAIN J, MUHME S, SCHONESHOFER M: Impaired renal 11P-oxidation of 9a-fluocortisol, an explanation for its mineralcorticoid potency.?Clin. Endocrine] Metab. (1994) 78:928–932.
   PubMed Web of Science ®Google Scholar
• OELKERS W: Diagnosis and therapy surveillance in Addison's disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity and aldosterone. I Clin. Endocrine] Metab. (1992) 75:259
   PubMed Web of Science ®Google Scholar
• FIAD TM, CONWAY JD, CUNNINGHAM SK, MCKENNA TJ: The role of plasma renin activity in evaluating the adequacy of mineralcorticoid replacement in primary adrenal insufficiency. (1996) Clin. Endocrine] 45:529–534.
   Google Scholar
• OELKERS W: Dehydroepiandrosterone for adrenal insufficiency. N Eng] j Med. (1999) 341:1073–1074.
   PubMed Web of Science ®Google Scholar
• ACHERMANN JC, SILVERMAN BL: Dehydroepiandrosterone replacement for patients with adrenal insufficiency. Lancet (2001) 357:1381–1382.
   PubMed Web of Science ®Google Scholar
• KROBOTH PD, SALEK FS, PITTENGER AL, FABIAN TJ, FRYE RE: DHEA and DHEA-S: a review Pharmacy] (1999) 39:327–348.
   Google Scholar
• ARLT W, CALLIES F, VAN VIJMEN JC et al.: Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Eng]?Med. (1999) 241:1013–1020.
   Google Scholar
• ••The first study showing a beneficial effectof DHEA replacement therapy in women with adrenal insufficiency.
   Google Scholar
• ARLT W, CALLIES F, VAN VLUMEN JC etal.: Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. j Cliii. Endocnno] Metab. (1998) 83:1928–1934.
   Google Scholar
• GEBRE-MEDHIN G, HUSEBYE ES, MALLMIN H et a]: Oral dehydroepiandrosterone (DHEA) replacement therapy in women with Addison's disease. (2000) Clin. Endocrine]. 52: 775–780.
   Google Scholar
• •A study indicating that the daily replacement dose of 50 mg of DHEA results in near physiological levels of DHEA and other adrenal androgens in women with Addison's disease, without severe side effects.
   Google Scholar
• HUNT PJ, GURNELL EM, HUPPERT FA et al: Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. ..J. Clin. Endocrine]. Metab. (2000) 85 :4650–4656.
   PubMed Web of Science ®Google Scholar
• ••A study indicating that DHEA replacement corrects the androgen steroid defect in males with PAT.
   Google Scholar
• CALLIES F, FASSNACHT M, VAN VLIJMEN JC et al.: Dehydroepiandrosterone replacement in women with adrenal insufficiency: effects on body composition, serum leptin, bone turnover, and exercise capacity. j art. Endocnitol. Metab. (2001) 86:1968–1972.
   Google Scholar
• •A study showing that DHEA replacement does not have a significant effect on carbohydrate metabolism, body composition, or exercise capacity in patients with adrenal insufficiency.
   Google Scholar